Cerus/$CERS
1D1W1MYTD1Y5YMAX
Capital at risk
About Cerus
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
- Ticker
- $CERS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 268
- Headquarters
- Concord, United States
- Website
- www.cerus.com
Cerus Metrics
BasicAdvanced
$538M
-
-$0.03
1.80
-
Price and volume
Market cap
$538M
Beta
1.8
52-week high
$3.47
52-week low
$1.38
Average daily volume
1.8M
Financial strength
Current ratio
1.834
Quick ratio
1.017
Long term debt to equity
0.615
Total debt to equity
1.086
Interest coverage (TTM)
-0.14%
Profitability
EBITDA (TTM)
0.066
Gross margin (TTM)
52.05%
Net profit margin (TTM)
-3.06%
Operating margin (TTM)
-0.73%
Effective tax rate (TTM)
-6.05%
Revenue per employee (TTM)
$830,000
Management effectiveness
Return on assets (TTM)
-0.48%
Return on equity (TTM)
-10.77%
Valuation
Price to revenue (TTM)
2.346
Price to book
7.68
Price to tangible book (TTM)
7.83
Price to free cash flow (TTM)
-284.224
Free cash flow yield (TTM)
-0.35%
Free cash flow per share (TTM)
-0.009
Growth
Revenue change (TTM)
15.09%
Earnings per share change (TTM)
-65.42%
3-year revenue growth (CAGR)
13.03%
10-year revenue growth (CAGR)
20.41%
3-year earnings per share growth (CAGR)
-50.42%
10-year earnings per share growth (CAGR)
-25.51%
What the Analysts think about Cerus
Analyst ratings (Buy, Hold, Sell) for Cerus stock.
Analyst projections of the future price of Cerus stock.
Bulls say / Bears say
Cerus reported 10% year-on-year product-revenue growth in the second quarter and raised the low end of its 2026 product guidance to $229m-$231m. INTERCEPT Fibrinogen Complex sales are expected to grow by about 40%-50%, giving the business a faster-growing product alongside its established platelet and plasma franchise. (Cerus 10-Q, Business Wire)
Cerus has added several potential growth catalysts: it submitted the INT200 platelet-device application to the FDA and increased the potential value of its BARDA red-blood-cell contract to $270.5m. Positive regulatory and clinical outcomes could open a much larger red-blood-cell opportunity than the current product base. (Cerus 10-Q, Yahoo Finance)
A new four-year supply agreement with France’s national blood establishment covers platelets, plasma and the INT200 device. The contract supports recurring European demand and gives Cerus a reference customer with a large national blood network, while international penetration remains low in some regions. (Business Wire, Cerus earnings call transcript)
Cerus remains loss-making and product gross margin fell to 51.4% from 55.2% a year earlier. The company also used $2.7m in operating cash during the quarter, so revenue growth has not yet translated into dependable cash generation. (Simply Wall St, Cerus 10-Q)
The main expansion opportunities are still dependent on approvals and trial results: the INT200 FDA decision is not expected until early 2027, while the red-blood-cell programme remains under European review and awaits its U.S. Phase 3 readout. Delays or disappointing data would push back the revenue upside investors are paying for. (Cerus 10-Q, Morningstar)
The balance sheet still carries meaningful financing risk: at 30 June, Cerus had $56.3m of cash and short-term investments, alongside a $35m term loan and $30.1m drawn on its revolver. With operating cash flow negative in the quarter, further investment or weaker sales could increase reliance on borrowing or future equity funding. (Cerus 10-Q, Cerus 8-K filing)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.
Cerus Financial Performance
Revenues and expenses
Cerus Earnings Performance
Company profitability
Upcoming events
No upcoming events
Cerus News
AllArticlesVideos
Funds containing Cerus
Fund name | Fund size | $CERS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.